Genome Editing/Genome Engineering Market Report 2025

The genome editing/genome engineering market size has grown rapidly in recent years. It will grow from $8.62 billion in 2024 to $10.2 billion in 2025 at a compound annual growth rate (CAGR) of 18.2%. The growth in the historic period can be attributed to increasing research in genetics and genomics, rise in genetic diseases, gene therapy advancements, investments in biotechnology and life sciences, potential for agricultural applications, application in model organisms.

The genome editing/genome engineering market size is expected to see rapid growth in the next few years. It will grow to $20.81 billion in 2029 at a compound annual growth rate (CAGR) of 19.5%. The growth in the forecast period can be attributed to emergence of prime editing, focus on ethical and regulatory frameworks, increasing adoption in drug discovery, therapeutic potential for genetic disorders, customization for gene function studies, growing interest in epigenome editing. Major trends in the forecast period include advancements in Crispr technology, growing applications in therapeutics, emergence of new genome editing tools, investments and partnerships, enhanced delivery systems, integration of artificial intelligence (ai) in genome editing design.

The increasing prevalence of cancer and other genetic disorders is anticipated to drive the growth of the genome editing and genome engineering market in the future. Cancer is a condition characterized by the uncontrolled growth of certain cells in the body, which can spread to other areas. Genome editing has the potential to rapidly engineer immune cells and oncolytic viruses for therapeutic purposes in cancer treatment. For instance, in February 2022, an article published by the World Health Organization (WHO), a Switzerland-based agency of the United Nations, reported that nearly 10 million deaths, or approximately one in six deaths, were attributed to cancer, making it the leading cause of death globally. Additionally, a June 2022 report from the Centers for Disease Control and Prevention (CDC), a US-based national public health agency, indicated that 1,752,735 new cases of invasive cancer were diagnosed in the US in 2019, including 863,830 women and 888,905 men. The overall incidence rate for all cancers was 439 per 100,000 individuals in the general population. Therefore, the rising prevalence of cancer and other genetic disorders is propelling the growth of the genome editing and genome engineering market.

An anticipated rise in research activities is set to propel the growth of the genome editing and genome engineering market in the future. Research activities involve systematic and organized efforts by individuals, teams, or institutions aimed at gathering, analyzing, interpreting, and generating new knowledge or insights within a specific field. Genome editing and genome engineering have emerged as pivotal drivers of the increasing research landscape, significantly reshaping scientific exploration. These groundbreaking tools enable researchers to precisely modify and understand the complex genetic structures of organisms, providing unmatched accuracy and flexibility. For example, in February 2024, The Office for National Statistics, a UK-based agency, reported that in 2022, UK businesses invested £49.9 billion ($65.29 billion) in research and development (R&D), marking an increase of £3 billion ($3.93 billion) or 6.4% compared to 2021. Consequently, the rise in research activities is fueling the growth of the genome editing and genome engineering market.

The genome editing or genome engineering market is witnessing a key trend in technological advancements in gene editing. Major companies are focusing on developing innovative technology solutions to enhance their position in the market. For instance, researchers at Kyoto University and the Institute of Evolutionary Biology (CSIC-Universitat Pompeu Fabra) have introduced a novel gene-editing method called Direct Parental CRISPR (DIPA-CRISPR). This technique offers a quick and effective means of editing genes in insects by injecting materials into developing eggs in female adults, bypassing the traditional method of microinjecting CRISPR material into insect embryos. The adoption of advanced gene-editing technologies is contributing to the efficiency and precision of genetic modifications.

Major companies operating in the genome editing or genome engineering market are engaging in strategic partnerships to fortify their positions. Strategic partnerships, such as the collaboration between Ionis Pharmaceuticals Inc. and Metagenomi, aim to expand and diversify technological capabilities. Ionis Pharmaceuticals Inc., a biotechnology company, partnered with Metagenomi, a genomic medicines company, to leverage their respective technologies and deliver transformative therapies focused on genetic targets. Such collaborations enable companies to pool resources, share expertise, and innovate collectively, fostering advancements in the genome editing or genome engineering field.

In September 2022, Lesaffre, a France-based microorganisms, healthcare and biotechnology company acquired Recombia Biosciences for an undisclosed amount. The acquisition aims to leverage Recombia Biosciences’ genome-editing technologies and accelerate the development of yeasts for sustainable production of fermented ingredients. Recombia Biosciences is a US-based biotechnology company.

Major companies operating in the genome editing/genome engineering market are Thermo Fisher Scientific Inc., Merck Group, Genscript Biotech Corp, Sangamo Therapeutics Inc., Lonza Group AG, Editas Medicine Inc., CRISPR Therapeutics AG, Agilent Technologies Inc., Intellia Therapeutics, bluebird bio Inc., Transposagen Biopharmaceuticals Inc., Tecan Trading AG, Precision BioSciences, PerkinElmer Inc., Cellectis S.A, Applied StemCell Inc., Bio-Rad Laboratories Inc., Bio-Techne, Creative Biogene, Cyagen Biosciences, Dharmacon Inc., Eurofins Genomics LLC, Evotec SE, GeneCopoeia Inc., Genewiz, Horizon Discovery Group PLC, Inscripta Inc., Integrated DNA Technologies Inc., MaxCyte Inc., New England Biolabs, Novartis International AG.

North America was the largest region in the gene editing or genome engineering market in 2024. Asia-Pacific is expected to be the fastest-growing region in the genome editing or genome engineering market report during the forecast period. The regions covered in the genome editing or genome engineering market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the genome editing or genome engineering market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Genome editing is a technique that allows scientists to modify the DNA of various organisms, including plants, bacteria, and animals. This technology enables the alteration of DNA, influencing physical characteristics such as eye color and the susceptibility to diseases. Genome editing is extensively used in research labs with animal models and cells to gain insights into diseases.

The main products and services in genome editing and genome engineering encompass reagents and consumables, software and systems, and services. Reagents and consumables are utilized at specific locations in the genome of a target organism to induce breaks, repairs, or mismatches, leveraging endogenous mechanisms to bring about specific changes in the DNA sequence. Consumables are items used until depletion and then disposed of, while reagents are compounds or substances that facilitate a reaction. Various technologies, including Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR), Transcription Activator-Like Effector Nuclease (TALEN), Zinc Finger Nucleases (ZFN), antisense, and others, are employed in genome editing. These technologies find applications in cell line engineering, genetic engineering, diagnostic applications, drug discovery and development, and various other fields. The users of genome editing technologies include biotechnology companies, pharmaceutical companies, academic and government research institutes.

The genome editing or genome engineering market research report is one of a series of new reports that provides genome editing or genome engineering market statistics, including genome editing or genome engineering industry global market size, regional shares, competitors with a genome editing or genome engineering market share, detailed genome editing or genome engineering market segments, market trends and opportunities, and any further data you may need to thrive in the genome editing or genome engineering industry. This genome editing or genome engineering market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The genome editing or genome engineering market includes revenues earned by entities through cell line engineering, animal genetic engineering, and plant genetic engineering. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.